Leitlinie „Behandlung der Akne“ - AWMF
Leitlinie „Behandlung der Akne“ - AWMF Leitlinie „Behandlung der Akne“ - AWMF
013/017 - Behandlung der Akne aktueller Stand: 02/2010 korrigierte Fassung: 10/2011 290. Lachnit-Fixson U, Kaufmann J. [Therapy of androgenization symptoms: double blind study of an antiandrogen preparation (SH B 209 AB) against neogynon (author's transl)]. Med Klin. 1977; 72: 1922-6. 291. Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand. 1990; 69: 61-5. 292. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster A, Doesburg W. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil Menopausal Stud. 1996; 41: 423-9. 293. Dieben TO, Vromans L, Theeuwes A, Bennink HJ. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception. 1994; 50: 373-82. 294. Aydinlik S, Lachnit-Fixson U, Lehnert J. [Reduced estrogen ovulation inhibitor in acne therapy. Double-blind study comparing Diane-35 to Diane]. Fortschr Med. 1986; 104: 547-50. 295. Colver GB, Mortimer PS, Dawber RP. Cyproterone acetate and two doses of oestrogen in female acne; a double-blind comparison. Br J Dermatol. 1988; 118: 95-9. 296. Fugere P, Percival-Smith R, Lussier-Cacan S, Tetrault C, Farquhar DJ. The comperative efficacy and safety of Diane-35 versus Diane-50 in the treatment of moderate to severe acne and seborrhea: 12-month results. Recent Res Gynecol Endocrinol. 1988; 1: 590-608. 297. Monk BE, Almeyda JA, Caldwell IW, Green B, Pelta D, Leonard J, Du Vivier A, Johnson K, Tolowinska I. Efficacy of low-dose cyproterone acetate compared with minocycline in the treatment of acne vulgaris. Clin Exp Dermatol. 1987; 12: 319-22. 298. Seaman HE, de Vries CS, Farmer RD. Differences in the use of combined oral contraceptives amongst women with and without acne. Hum Reprod. 2003; 18: 515- 21. 299. Tan J. Hormonal treatment of acne: Review of current best evidence. J Cut Med Surgery. 2005; 8: 11-15. 300. Kaiser E. [Effect of a new hormonal contraceptive (Neo-Eunomin) in females with androgenization symptoms]. Geburtshilfe Frauenheilkd. 1984; 44: 651-5. 301. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology. 2001; 203: 38-44. 302. Moore C, Luderschmidt C, Moltz L, Oettel M, Klinger G, Schreiber G. Antiandrogenic propertiesof the dienogest-containing oral contrceptive Valette. Drugs of Today (Barc). 1999; 35: 69-78. 303. Palombo-Kinne E, Schellschmidt I, Schumacher U, Graser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception. 2009; 79: 282-9. 304. Foster RH, Wilde MI. Dienogest. Drugs. 1998; 56: 825-33; discussion 34-5. 305. Maloney JM, Dietze P, Jr., Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl Seite 124 von 136
013/017 - Behandlung der Akne aktueller Stand: 02/2010 korrigierte Fassung: 10/2011 estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol. 2008; 112: 773-81. 306. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002; 69: 2-15. 307. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000; 43: 498-502. 308. Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev. 2009: CD000194. 309. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 1994; 61: 281-7. 310. Carmina E, Lobo RA. A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women. Clin Endocrinol (Oxf). 2002; 57: 231- 34. 311. Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother. 1995; 29: 736-42. 312. Wang HS, Wang TH, Soong YK. Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea. Changgeng Yi Xue Za Zhi. 1999; 22: 423-32. 313. Palatsi R, Hirvensalo E, Liukko P, Malmiharju T, Mattila L, Riihiluoma P, Ylostalo P. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol. 1984; 64: 517-23. 314. Upton GV, Corbin A. The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive. Yale J Biol Med. 1989; 62: 445-57. 315. Leyden J, Shalita A, Hordinsky M, Swinyer L, Stanczyk FZ, Weber ME. Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: A randomized, placebocontrolled trial. J Am Acad Dermatol. 2002; 47: 399-409. 316. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril. 2001; 76: 461-8. 317. Lemay A, Dewailly SD, Grenier R, Huard J. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel. J Clin Endocrinol Metab. 1990; 71: 8-14. 318. Henzl MR. Norgestimate. From the laboratory to three clinical indications. J Reprod Med. 2001; 46: 647-61. 319. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997; 37: 746-54. Seite 125 von 136
- Seite 73 und 74: 013/017 - Behandlung der Akne aktue
- Seite 75 und 76: 013/017 - Behandlung der Akne aktue
- Seite 77 und 78: 013/017 - Behandlung der Akne aktue
- Seite 79 und 80: 013/017 - Behandlung der Akne aktue
- Seite 81 und 82: 013/017 - Behandlung der Akne aktue
- Seite 83 und 84: 013/017 - Behandlung der Akne aktue
- Seite 85 und 86: 013/017 - Behandlung der Akne aktue
- Seite 87 und 88: 013/017 - Behandlung der Akne aktue
- Seite 89 und 90: 013/017 - Behandlung der Akne aktue
- Seite 91 und 92: 013/017 - Behandlung der Akne aktue
- Seite 93 und 94: 013/017 - Behandlung der Akne aktue
- Seite 95 und 96: 013/017 - Behandlung der Akne aktue
- Seite 97 und 98: 013/017 - Behandlung der Akne aktue
- Seite 99 und 100: 013/017 - Behandlung der Akne aktue
- Seite 101 und 102: 013/017 - Behandlung der Akne aktue
- Seite 103 und 104: 013/017 - Behandlung der Akne aktue
- Seite 105 und 106: 013/017 - Behandlung der Akne aktue
- Seite 107 und 108: 013/017 - Behandlung der Akne aktue
- Seite 109 und 110: 013/017 - Behandlung der Akne aktue
- Seite 111 und 112: 013/017 - Behandlung der Akne aktue
- Seite 113 und 114: 013/017 - Behandlung der Akne aktue
- Seite 115 und 116: 013/017 - Behandlung der Akne aktue
- Seite 117 und 118: 013/017 - Behandlung der Akne aktue
- Seite 119 und 120: 013/017 - Behandlung der Akne aktue
- Seite 121 und 122: 013/017 - Behandlung der Akne aktue
- Seite 123: 013/017 - Behandlung der Akne aktue
- Seite 127 und 128: 013/017 - Behandlung der Akne aktue
- Seite 129 und 130: 013/017 - Behandlung der Akne aktue
- Seite 131 und 132: 013/017 - Behandlung der Akne aktue
- Seite 133 und 134: 013/017 - Behandlung der Akne aktue
- Seite 135 und 136: 013/017 - Behandlung der Akne aktue
013/017 - Behandlung <strong>der</strong> Akne aktueller Stand: 02/2010<br />
korrigierte Fassung: 10/2011<br />
290. Lachnit-Fixson U, Kaufmann J. [Therapy of androgenization symptoms: double blind<br />
study of an antiandrogen preparation (SH B 209 AB) against neogynon (author's<br />
transl)]. Med Klin. 1977; 72: 1922-6.<br />
291. Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation<br />
inhibitors containing cyproterone acetate or desogestrel in the treatment of<br />
hyperandrogenic symptoms. Acta Obstet Gynecol Scand. 1990; 69: 61-5.<br />
292. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster<br />
A, Doesburg W. Effects on acne of two oral contraceptives containing desogestrel and<br />
cyproterone acetate. Int J Fertil Menopausal Stud. 1996; 41: 423-9.<br />
293. Dieben TO, Vromans L, Theeuwes A, Bennink HJ. The effects of CTR-24, a biphasic<br />
oral contraceptive combination, compared to Diane-35 in women with acne.<br />
Contraception. 1994; 50: 373-82.<br />
294. Aydinlik S, Lachnit-Fixson U, Lehnert J. [Reduced estrogen ovulation inhibitor in<br />
acne therapy. Double-blind study comparing Diane-35 to Diane]. Fortschr Med. 1986;<br />
104: 547-50.<br />
295. Colver GB, Mortimer PS, Dawber RP. Cyproterone acetate and two doses of<br />
oestrogen in female acne; a double-blind comparison. Br J Dermatol. 1988; 118: 95-9.<br />
296. Fugere P, Percival-Smith R, Lussier-Cacan S, Tetrault C, Farquhar DJ. The<br />
comperative efficacy and safety of Diane-35 versus Diane-50 in the treatment of<br />
mo<strong>der</strong>ate to severe acne and seborrhea: 12-month results. Recent Res Gynecol<br />
Endocrinol. 1988; 1: 590-608.<br />
297. Monk BE, Almeyda JA, Caldwell IW, Green B, Pelta D, Leonard J, Du Vivier A,<br />
Johnson K, Tolowinska I. Efficacy of low-dose cyproterone acetate compared with<br />
minocycline in the treatment of acne vulgaris. Clin Exp Dermatol. 1987; 12: 319-22.<br />
298. Seaman HE, de Vries CS, Farmer RD. Differences in the use of combined oral<br />
contraceptives amongst women with and without acne. Hum Reprod. 2003; 18: 515-<br />
21.<br />
299. Tan J. Hormonal treatment of acne: Review of current best evidence. J Cut Med<br />
Surgery. 2005; 8: 11-15.<br />
300. Kaiser E. [Effect of a new hormonal contraceptive (Neo-Eunomin) in females with<br />
androgenization symptoms]. Geburtshilfe Frauenheilkd. 1984; 44: 651-5.<br />
301. Worret I, Arp W, Zahradnik HP, Andreas JO, Bin<strong>der</strong> N. Acne resolution rates: results<br />
of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA<br />
(Belara) and EE/LNG (Microgynon). Dermatology. 2001; 203: 38-44.<br />
302. Moore C, Lu<strong>der</strong>schmidt C, Moltz L, Oettel M, Klinger G, Schreiber G.<br />
Antiandrogenic propertiesof the dienogest-containing oral contrceptive Valette. Drugs<br />
of Today (Barc). 1999; 35: 69-78.<br />
303. Palombo-Kinne E, Schellschmidt I, Schumacher U, Graser T. Efficacy of a combined<br />
oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the<br />
treatment of papulopustular acne in comparison with placebo and 0.035 mg<br />
ethinylestradiol/2 mg cyproterone acetate. Contraception. 2009; 79: 282-9.<br />
304. Foster RH, Wilde MI. Dienogest. Drugs. 1998; 56: 825-33; discussion 34-5.<br />
305. Maloney JM, Dietze P, Jr., Watson D, Niknian M, Lee-Rugh S, Sampson-Lan<strong>der</strong>s C,<br />
Korner P. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl<br />
Seite 124 von 136